Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-type-1 Polarizing Dendritic Cells pulsed with HIV peptides
- Development stage
- Unknown
- Lead developer
- University of Sao Paulo General Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides is an autologous therapeutic vaccine being developed by the University of São Paulo General Hospital for the treatment of HIV infection. The therapy involves harvesting a patient's monocytes, differentiating them into alpha-type-1 polarizing dendritic cells in vitro, and pulsing them with HIV-specific antigens, including peptides from the Gag, Pol, and Nef proteins. These matured and activated antigen-presenting cells are designed to induce robust HIV-specific CD4+ and CD8+ T-cell immune responses, aiming to enhance viral control in individuals on antiretroviral therapy (ART), particularly during analytical treatment interruption (ATI).
- Other names
- aDC1-HIV vaccineaDC-1-HIV vaccineaDC 1-HIV vaccineaDC1 dendritic cell vaccineaDC-1 dendritic cell vaccineaDC 1 dendritic cell vaccineAlpha-type-1 Polarizing Dendritic Cells pulsed with HIV peptides-University of Sao Paulo General Hospital-HIV infectionAlpha-type1 Polarizing Dendritic Cells pulsed with HIV peptides-University of Sao Paulo General Hospital-HIV infectionAlpha-type 1 Polarizing Dendritic Cells pulsed with HIV peptides-University of Sao Paulo General Hospital-HIV infection
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Alpha-type-1 Polarizing Dendritic Cells pulsed with HIV peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-type-1 Polarizing Dendritic Cells pulsed with HIV peptides.